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Interleukin-6 (IL-6) is a potential mediator of systemic effects of Chronic Obstructive Pulmo-
nary Disease (COPD).
In the present caseecontrol study we investigated the association of promoter polymor-
phisms of this gene and COPD in a cohort of 191 patients, smokers without COPD (nZ 75)
and a healthy control population (nZ 296). Besides spirometry, exercise capacity (6MWD,
6 min walking distance) and body mass index (BMI) were measured in COPD patients. Genotyp-
ing of the IL-6 polymorphisms at positions 174, 572 and 597 was performed.
The 597G/A and 174G/C polymorphisms were not associated with the disease. However,
the 572G/C polymorphism was significantly associated with COPD susceptibility under a dom-
inant model of inheritance. The frequency of the genotypes containing the C allele was signif-
icantly lower in the COPD cases (9.9%) compared with the healthy control group (16.9%) and
smokers (23.1%), (ORZ 0.46, pZ 0.032 and ORZ 0.28, pZ 0.012, respectively). The GCG
(597/572/174) haplotype was significantly associated with the disease (ORZ 0.37,
pZ 0.022, COPD cases vs. healthy subjects and ORZ 0.17, pZ 0.011, COPD cases vs.
smokers). Moreover, a borderline association was also found for the 572G allele and hypox-
emia (PaO2< 60 mmHg) (pZ 0.05). Our data suggest that the IL-6572C allele may confer a di-
minished risk of developing COPD.
ª 2008 Elsevier Ltd. All rights reserved.2 600675; fax: þ34 922 600562.
@hotmail.com (E. Co´rdoba-Lanu´s).
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Chronic Obstructive Pulmonary Disease (COPD) is a preva-
lent disease expected to be the third cause of mortality in
the year 2020. Tobacco smoking is undoubtedly the most
important risk factor for COPD but the reason why only 15e
25% of smokers develop clinically important disease is still
unknown.1 COPD is an inflammatory pulmonary disease and
appears to be associated with the presence of increased
systemic inflammatory markers.
Different cytokines may be part of the inflammatory
response of the airways in COPD. It is likely that variations
in the phenotypic expression of these cytokines are a result
of differences in the response to basic molecularecellular
cascades, which in turn are due to genetic variations in the
inflammatory response to environmental irritants. The
association of peripheral inflammatory mediators such as
tumour necrosis factor-alpha (TNF-a), C-reactive protein
(CRP) and interleukin-6 (IL-6) with abnormalities in body
composition, peripheral muscle performance, or functional
performance is increasingly being described.2,3 IL-6 is a po-
tential mediator of inflammation in COPD.4 It has been
shown to be increased in serum, exhaled breath condensate
and sputum during stable conditions and exacerbation,4 to
predict a faster decline in FEV1,
5 to be closely related with
weight loss and muscle wasting,2 to be associated with low
exercise capacity.6 In addition, it has been found to decline
after oral and inhaled corticosteroid therapy.7
Polymorphisms in the interleukin-6 gene promoter
region appear to be related to higher cytokine plasmatic
levels.8 The most studied one, the 174 (G/C), was associ-
ated with increased risk of cardiovascular events and
related risk factors such as CRP, fibrinogen and hyperten-
sion.9,10 Polymorphism 572 (G/C) has also been related
with CRP levels and bone resorption markers.11 Two previ-
ous studies analysed the association between the SNP
174 (G/C) in the IL-6 promoter gene and COPD, both
with negative results.12,13
Our aim in this study was to investigate the importance
of certain variants/haplotypes of the IL-6 gene polymor-
phisms as possible genetic markers accounting for individ-
ual COPD susceptibility in a Spanish population.
Methods
Study design
We included in this study 563 Caucasian individuals divided
into three groups, COPD patients, smokers without COPD
and healthy controls. Outpatients with COPD and a wide
range of severity of the disease were recruited from
a pulmonary clinic at Hospital Universitario N S de Cande-
laria (Tenerife, Spain) from August 2002 to May 2007.
Patients were included using the following criteria:
age> 40 years, history of smoking more than 20 pack-years
and a post-bronchodilator FEV1/FVC of less than 0.7 mea-
sured 20 min after the administration of 400 mg of inhaled
albuterol. Patients were evaluated within 6 weeks of enrol-
ment. Pulmonary function test, spirometry and lung
volumes were measured according to ATS-ERS guidelines14
using the European Community for Steel and Coal asreference values.15 The arterial oxygen tension (PaO2)
was measured at rest, breathing room air and in the sitting
position. Severe hypoxemia was defined by PaO2 val-
ues< 60 mmHg. We also tested the exercise capacity by
using the better of two 6-min walking distance (6MWD)
tests separated by at least 30 min following the ATS recom-
mendations.16 Low exercise capacity was defined by
a 6MWD value< 350 m. The body mass index (BMI) was cal-
culated as the weight in kilograms divided by the square of
the height in meters. Low body mass index was defined by
a BMI value 21. All patients were clinically stable (no
exacerbation for at least 2 months) at the time of evalua-
tion. Patients were excluded if they had history of other
confounding diseases like asthma or bronchiectasis. The
healthy control group consisted of 296 individuals without
respiratory disease and no smoking history from an ongoing
general adult population cohort named CDC project in the
Canary Islands.17 This cohort was randomly selected as
a representative sample of the general Canarian population
aged between 30 and 75 years. Finally, the third group con-
sisted of current smokers nZ 75 with cumulative cigarette
consumption of >15 pack-years and normal lung function
(FEV1 80% pred.; FEV1/FVC 70%). These subjects were
recruited from the outpatient clinics of the Hospital or
from the above cited CDC project. Ancestry minimized
any possible effect of population structure on our
estimations.18
This study was approved by the Ethics Committee of the
Hospital and written informed consent was obtained from
all participants.
Determination of IL-6 promoter polymorphisms
Venous blood was collected from each individual and total
genomic DNA was extracted using the commercially avail-
able GFX Kit (Ammersham Pharmacia).
In order to determine the IL-6 promoter polymorphisms
at positions 174, 572 and 597 by PCR-RFLP we used the
following primer: 50-CTGAAGCAGGTGAAGAAAGT-30 and 50-
GTCTCAACCCCCAATAAATA-30, which amplified a 673 base
pairs DNA fragment. PCR conditions were: 94 C for 5 min
followed by 30 cycles of 94 C 30 s, 59 C 30 s and 72 C
30 s with a final extension step of 72 C 7 min. PCR amplifi-
cations were carried out in 25 ml reactions containing 50 ng
of template DNA, buffer 1 [16 mM (NH4)2SO4, 67 mM Trise
Hcl (pH8.8)], 2 mM MgCl2, 200 mM of each dNTP (Promega),
0.3 mM of each primer and 0.5 U of Taq polymerase
(Ecogen/Bioline). Amplification was performed using
a Gene Amplificator PCR System 2700 (Applied Biosystem).
The PCR products were digested at 37 C with NlaIII (New
England Bio Labs.) to detect the 174 polymorphism,
BsrB1 (New England Bio Labs) to detect the 572 polymor-
phism and Fok1 (New England Bio Labs) to detect the 597
polymorphism. The digested products were analysed by
agarose gel electrophoreses with 2% (1:1 agarose:Nusieve)
gels run in 1 TBE buffer. Approximately, 20% of the
samples were genotyped in duplicate in order to ascertain
an optimal genotyping quality. Moreover, as a confirma-
tional method, a random number of samples (patients and
control subjects) were genotyped by sequencing on an ABI
PRISM 310 Genetic Analyser (Applied Biosystems). DNA se-
quencing was carried out on both strands using BigDye
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with the amplification primers used under manufacturer’s
recommendations.Statistical analyses
Assuming a probability of disease of 0.01, a risk genotype
frequency in population of 0.6 and an odds ratio (OR) of 1.8
with a two-sided p value of 0.05, and a caseecontrol design
with a 1:3 ratio, by means of Power 3.9, we estimated that
we would need at least 140 cases to reach a power of more
than 80% under a recessive model of inheritance.19
Allele and genotype distributions in the patient and
control groups were compared using contingency tables and
c2 test for independence. Haplotype reconstruction from
biallelic polymorphisms, disequilibrium values and Hardye
Weinberg test were calculated using the GENEPOP v3.4
Haploview v3.2 and PHASE v2.1 software programmes.20e22
The EPIDAT v3.0 database was used to calculate OR and
their 95% confidence intervals (CI), to estimate the geno-
type relative risks. By using the software SPSS v13 (SPSS,
Inc.), adjusted odd ratios for potential confounding factors
were computed with a multivariate logistic regression anal-
ysis, although maintaining in the model the variables that
remained significant at p< 0.05. Codominant and additive
models were tested first and then dominant and recessive
models were tested to see if those models fit better but
only when there was a significant association in the initial
analysis. Correction for multiple testing was performed by
calculating the effective number of independent marker
loci based on pairwise LD between genotyped SNPs.23
Demographic and main clinical data are presented as
percentage and mean SD. We explored for differences
between each polymorphism and clinical variables using
Student’s t-test for variables with approximately normal
distribution, ManneWhitney U rank test for variables with-
out normal distribution, and Fisher Exact T or Pearson c2
test for nominal and categorical variables by using the soft-
ware SPSS v13 (SPSS, Inc). A two-sided p value of <0.05 was
considered significant.Table 1 Demographic characteristics of COPD patients, smoker
Variable Cases nZ 191 Smoking
Gender
Male (%) 75 48
Age (years)a 62 10 48 9
Smoking history (pack-years)b,a 61 27 35 18
FEV1
a 1.55 0.7 3 1
FEV1 (%) pred.
a 57 21 102 15
FVC (%) pred.a 87 23 108 16
FEV1/FVC
a 51 12 79 6
6MWD (m) (nZ 139)a 490 86 e
BMI (Kg/m2)a 27 5 e
PaO2 (mmHg) (nZ 138)
a 72 11 e
FEV1: forced expiratory volume in 1 s; FVC: forced expiratory volume
Percentage compared by c2 test; mean SD by ANOVA or Student’s t
a mean SD.
b Number of packs of cigarettes smoked per day number of yearsResults
Baseline demographic data of the groups recruited for this
study are shown in Table 1. One hundred and ninety-one pa-
tients with COPD (49 females/142 males, mean age 62 10
years) with airflow obstruction (57% median FEV1) were
genotyped in the current study. There were significant
differences in several potential confounding factors be-
tween the three populations. Therefore, the associations
of genotypes and COPD were analysed by logistic regression
to adjust for these variables.
Alleles at the individual loci studied in all groups were in
HardyeWeinberg equilibrium. The frequencies of the minor
alleles of the IL-6 SNPs are represented in Fig. 1. The IL-6
polymorphisms at positions 597 (G/C) and 174 (G/A)
were in strong allelic association (597 G with 174 G,
D0Z 0.96, r2Z 0.84, p< 0.001).
In this association study the additive genetic model was
tested first. The 597(G/C) and 174 (G/A) SNPs were not
associated with COPD susceptibility, however, the IL-6
572 G> C (rs1800796) polymorphism was significantly as-
sociated with the disease (Table 2). Dominant and recessive
(not shown) models were then tested for this polymor-
phism. The frequency of the 572 genotypes containing
the C allele was significantly lower in the COPD cases
(9.9) compared with the healthy control group (16.9). The
association yielded an odds ratio (OR) of 0.54, 95% confi-
dence intervals (95% CI)Z 0.31e0.95, pZ 0.029. After ad-
justing for the variables’ gender and age the multiple
logistic regression analysis resulted in a significant associa-
tion of the 572 SNP with COPD, ORZ 0.46, 95% confidence
intervals (95% CI)Z 0.22e0.95, pZ 0.032, under a domi-
nant model of inheritance (Table 3). When the association
was tested between the COPD cases and the smokers group,
again only the IL-6 572 G> C SNP was significantly associ-
ated with the disease (Table 2). Dominant and recessive
models were tested for this polymorphism. The frequency
of the allele C carriers was significantly lower in the COPD
cases (9.9) compared with the smoking control group
(23.1) yielding an odds ratio (OR) of 0.41, 95% confidence
intervals (95% CI)Z 0.20e0.84, pZ 0.017. This results and healthy individuals included in the association study
controls nZ 75 Healthy controls nZ 296 p-Value
<0.0001
44
48 10 <0.0001
1 3 <0.0001
e <0.0001
e <0.0001
e <0.0001
e <0.0001
e
e
e
; % pred.: percent predicted; BMI: body mass index.
-test.
smoking.
Figure 1 Minor allele distribution of the IL-6 SNPs in the
three groups included in the study. The distribution of the C al-
lele of the rs1800796 (572) SNP differed significantly among
COPD cases, healthy controls and smokers (pZ 0.05).
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ing factors as age, gender and smoking pack/year (ORZ
0.28, 95% confidence intervals (95% CI)Z 0.10e0.77, pZ
0.012) under a dominant genetic model (Table 3). The
obtained p values were corrected for multiple testing by
the effective number of independent tests2 resulting in
a significant association for allele C carriers of the 572
SNP only between the COPD cases and the smoking control
group (adjusted pZ 0.028).
The three SNPs in the IL-6 promoter gene identified four
common haplotypes (597/572/174): GGG, AGC, GCG
and GGC, with frequencies >1%. The frequencies estimated
using PHASE based on LD between the SNPs are presented in
Fig. 2. The haplotype distribution showed a global signifi-
cant association p-valueZ 0.05 between the COPD patients
and the healthy control group, and pZ 0.007 between
COPD patients and smokers. The haplotype GCG was associ-
ated with COPD yielding an adjusted (OR)Z 0.37, 95%
confidence intervals (95% CI)Z 0.16e0.87, pZ 0.022
when compared the COPD cases with healthy subjects.
This haplotype was also associated with the disease in the
analysis with smoking individuals resulting in an adjusted
ORZ 0.17, 95% confidence intervals (95% CI)Z 0.04e0.66,Table 2 Association tests of IL-6 genotypes and COPD between
SNP (position) Genotype COPD
cases
(nZ 191)
Healthy
controls
(nZ 296)
Smoking
controls
(nZ 75)
OR
vs
rs1800795
(IL-6 174)
GG 82 (42.9) 128 (43.2) 31 (41.3)
GC 82 (42.9) 131 (44.3) 33 (44) 0.
CC 27 (14.1) 37 (12.5) 11 (14.7)
rs1800797
(IL-6 597)
GG 88 (46.1) 128 (43.2) 38 (50.6)
GA 73 (38.2) 133 (44.9) 27 (36) 0.
AA 30 (15.7) 35 (11.8) 10 (13.4)
rs1800796
(IL-6 572)
GG 172 (90.1) 246 (83.1) 59 (78.6)
GC 18 (9.4) 49 (16.6) 16 (21.3) 0.
CC 1 (0.5) 1 (0.3) 0
Data are presented as n (%). OR: odds ratio; CI: confidence interval.
a Multivariate logistic regression was used to adjust for potential conpZ 0.011. This association remained significant after
correction for multiple testing (adjusted pZ 0.025).
We were particularly interested in studying the relation-
ship between these SNPs and certain high risk subgroups of
COPD (low BMI, low exercise capacity and severe hypox-
emia). The analysis resulted in a borderline association for
the 572G allele and the subgroup of patients with severe
hypoxemia (c2Z 3.66, pZ 0.055). No relation was found
for this polymorphism and the other clinical variables.
Discussion
We have studied the influence of IL-6 gene polymorphisms
in the susceptibility to COPD in the Spanish population. To
our knowledge, this is the first caseecontrol study that
analysed the -572 polymorphism and found a positive asso-
ciation between the e572C allele and COPD.
There are only two previous reports analysing the
relating single nucleotide polymorphisms of the IL-6 gene
and COPD. In the first study, Seifart et al.12 analysed 113
patients and 2 control groups of 356 individuals and did
not find significant genotype differences for the 174 SNP
and the presence of COPD. In the second one, Broekhuizen
et al.13 also studying the 174 SNP in 99 patients stratified
by cachexia did not find any association between the poly-
morphism and COPD. Similarly, in the present study, we did
not find significant differences in the distribution of the
174 SNP between COPD patients and the two control
groups. The presence of COPD has not been previously
related to IL-6 572 polymorphism. This SNP has been asso-
ciated to other diseases. Bennermos et al. found a border-
line association between the IL-6 572G allele and future
cardiovascular death or a new myocardial infarction, and
no increased risk was noted for the 174(G/C) SNP.24
COPD is known to be associated with increased levels of
systemic markers of inflammation, such as acute-phase
proteins, IL-6, C-reactive protein (CRP) and TNF-a.2,3 Only
some people exposed to cigarette smoke develop COPD, in-
dicating that genetic factors are important determinants of
susceptibility. Thus, genetic polymorphisms that determine
the rate of acute-phase protein production would be impor-
tant genetic risk factors for COPD. Three studies havepatients, healthy controls and the smoking control group
(95% CI) COPD
. healthy controls
p-Valuea OR (95% CI) COPD
vs. smoking controls
p-Valuea
96 (0.68e1.35) 0.794 0.95 (0.57e1.57) 0.838
94 (0.67e1.31) 0.707 1.17 (0.71e1.92) 0.534
47 (0.24e0.95) 0.033y 0.30 (0.12e0.79) 0.014y
yp< 0.05 (adjusted).
founding factors including age, gender and pack/years of smoking.
Table 3 Association tests of IL-6 572G/C polymorphism and recorded variables under a dominant model of inheritance using
multiple logistic regression analysis
Included variablea COPD vs. healthy controls COPD vs. smoking controls
Bb ORadjusted 95% CI p-Value* B
b ORadjusted 95% CI p-Value*
Dominant model
GCþ CC 0.78 0.46 0.22e0.95 0.032 1.27 0.28 0.10e0.77 0.012
Age 0.12 1.13 1.10e1.16 <0.001 0.10 1.10 1.06e1.15 <0.001
Gender 1.03 2.81 1.74e4.55 <0.001 0.25 1.29 0.61e2.71 0.506
Smoking (pack/year) 0.03 1.04 1.01e1.06 0.002
a Age, gender and smoking history (pack/years) were maintained in the model since they were significantly associated (p< 0.05).
b Regression coefficient, OR: odds ratio; CI: confidence interval.
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cytokine levels. Ferrari et al. found that the 572C allele
which showed an increased promoter activity in response
to IL-1b and TNF-a in transfected cells was associated
with higher levels of C-reactive protein and a marker of
bone resorption (urinary CTx).12 Brull et al. studying the
influence of IL-6 genotype after coronary artery bypass
surgery suggested that the SNP 572 (G/C) is indeed func-
tional based on higher (65%) 6-h IL-6 levels observed in
carriers of the 572C allele.25 In the last study, Shin et
al. found that serum concentrations of CRP in subjects
homozygous for the 572G allele, were significantly higher
only in smokers, therefore, suggesting that individuals with
the G/G genotype of the IL-6 572C>G polymorphism, who
represent about 7% of Korean population, have an elevated
inflammatory response to cigarette smoking.26 However,
the allele frequency for this SNP in the Korean population
is different from Caucasians: major allele C (75%) for the
first ones and major allele G (95%) for the second ones,
which is consistent with previous findings.
In our study the IL-6 haplotype (597/572/174) GCG
was significantly associated with COPD conferring a dimin-
ished risk of developing the disease. Haplotype analysis of
the candidate gene is of interest since in other studies they
characterized the combined effects of several SNPs on
expression levels of IL-6.27 Interestingly, in an in vitroFigure 2 IL-6 (597/572/174) haplotypes frequency dis-
tributions in COPD patients, healthy controls and smokers.
Global haplotype association value: pZ 0.05 between COPD
cases and healthy controls, and pZ 0.007 between COPD pa-
tients and smokers.study, it was demonstrated that leucocytes from homozy-
gous carrier of the GGG (597/572/174) haplotype pro-
duced the highest amount of IL-6.28
The association observed for the IL-6 572 (G/C) poly-
morphism as a potential genetic risk factor for COPD was
unchanged after adjustment for possible confounding
factors as age, gender and smoking pack-years in the
multivariate analysis performed, and after correcting for
multiple testing. This supports that the association found is
a robust effect in the population studied.
Interestingly, we found an association between de-
creased arterial oxygen tension and the 572G allele.
However, the correlation between the 572G allele and
low exercise capacity (6MWD) and low BMI was not statis-
tically significant. In this context these results should be
interpreted cautiously, because they might be due to the
small sample size of the different subgroups of COPD.
Further studies in this field are needed taking into account
previous researches that reflect the importance of arterial
oxygen tension in COPD. It is well known that PaO2 predicts
survival, the development of pulmonary hypertension and
determines the need of oxygen therapy in COPD patients.
Hypoxemia triggers oxidative stress and inflammation in
COPD patients.29 In an in vivo study, higher levels of 8-epi-
Prostaglandin F2a, the gold indicator of oxidative stress
were observed in Korean smokers with the e572G/G geno-
type when compared with C/G or C/C.26 The association be-
tween hypoxemia and the 572 IL-6 gene polymorphism
found in our study agrees with our previous observation
where CRP levels were inversed correlated with PaO2, sug-
gesting the importance of inflammatory markers as predic-
tors of COPD prognosis.3 Our results are reinforced by the
findings of van Helvoort et al. who studied the influence of
systemic inflammation and oxidative stress at rest and
during exercise in patients with COPD after supplemental
oxygen. In this study, IL-6 has been involved in the possible
mechanism of action that could explain the benefits of
oxygen therapy in COPD patients.30 Joppa et al. found
that significant pulmonary hypertension in COPD patients
had higher levels of circulating CRP and TNF-a. In this study
they suggest the major role of systemic inflammation in pul-
monary hypertension in COPD patients as they found that
PaO2 and CRP levels in serum significantly predicted systolic
pulmonary artery pressure thus, indicating the contribution
of hypoxemia and inflammation in the pathogenesis of pul-
monary hypertension.31 Moreover, Yokoe et al. found that
CRP and IL-6 levels and spontaneous production of IL-6 by
monocytes are elevated in patients with obstructive sleep
1810 E. Co´rdoba-Lanu´s et al.apnea syndrome and that these levels are decreased by
nasal continuous positive airway pressure.32 The cross
sectional nature of our study does not allow causal relation-
ship between hypoxemia and this genetic variant.
It is interesting to explore whether the risk effects of the
SNP 572 are mediated through plasma levels of the
cytokine. Further studies based on functional analysis are
needed to understand the implication that the 572 variant
might have over the disease process in the Spanish
population analysed. Circulating levels of IL-6 are regulated
at the level of expression. The transcription of this cytokine
is regulated by the several transcription factors: NF-IL6, NF-
kB, Fos/Jun, cellular retinol-binding protein (CRBP) and the
glucocorticoid receptor. Although the SNP 572 (GC) is
near a potential glucocorticoid receptor element at posi-
tion 557 to e55227 there are no known phylogenetically
conserved transcription factors binding to this site, How-
ever, its contribution in the regulation of gene expression
cannot be ruled out.
The present study was conducted to evaluate the
influence on COPD of three promoter IL-6 SNPs that have
been investigated in a variety of diseases. It has been
demonstrated that IL-6 promoter polymorphisms e174 (G/
C) and e572 (G/C) are key regulators of IL-6 gene and
downstream protein levels in vitro and in vivo.8,11,25
This study presents some limitations: first, the selected
SNPs did not reflect the full LD pattern in the whole gene.
However, the e174 (G/C) and e572 (G/C) are tag SNPs of
a LD block, and the e174 is in strong LD with at least eight
other SNPs across the gene (Seattle SNP database, http://
www.pga.gs.washingtom.edu). Second, population stratifi-
cation should be addressed in this kind of studies. Even
though, it is known that human populations from Spain, in-
cluding Canary Islands, are highly homogenous in their ge-
netic background.18 In order to reduce the possibility of
subtle population stratification we included 100% Canarian
individuals in our controls groups (smokers and non-smoker)
with at least two generations of ancestors from the islands.
Third, in the present study we did not analyse a second co-
hort to replicate our results. Finally, the sample analysed
might be small, particularly the subgroups of COPD pa-
tients. However, this represents the first study boarding
the influence of the IL-6 572 (G/C) polymorphism and
COPD. Our findings support the design of larger studies of
populations undergoing this pathology, where this genetic
variant might be included in the analyses to help determine
its importance in the susceptibility to COPD.
In summary, the major finding of our study is that the
572C allele may confer a diminished risk of developing
COPD in the Spanish population. This SNP could be associ-
ated with hypoxemia, an important prognostic clinical
variable in COPD. Further analysis confirming the associa-
tion found may shed some light to the possible role of the
polymorphism 572 as a genetic risk factor in linkage
disequilibrium with other genetic marker/s or whether it
may be the causal locus in the pathogenesis of COPD.Acknowledgements
To Bartolome´ Celli, MD, PhD from the Pulmonary and
Critical Care Department Caritas, St. Elizabeth’s MedicalCenter, Boston, MA, USA for his valuable comments in the
intellectual contents and for revising critically this manu-
script. This research was supported by grants of the
Fundacio´n Canaria de Investigacio´n y Salud (FUNCIS) and
the Sociedad Espan˜ola de Neumologı´a y Cirugı´a Tora´cica
(SEPAR).
Conflict of interest
None of the authors has declared any conflict of interest
related to the work presented.
References
1. Lokke A, Lange P, Scharling H, Fabricius P, Vestbo J. Developing
COPD: a 25 year follow up study of the general population.
Thorax 2006;61:935e9.
2. Eid AA, Lonescu AA, Nixon LS, Lewis-Jenkins V, Matthews SB,
Griffiths TL, et al. Inflammatory response and body composi-
tion in chronic obstructive pulmonary disease. Am J Respir
Crit Care Med 2001;164:1414e8.
3. de Torres JP, Cordoba-Lanus E, Lopez-Aguilar C, Muros de
Fuentes M, Montejo de Garcini A, Aguirre-Jaime A, et al. C-
reactive protein levels and clinically important predictive out-
comes in stable COPD patients. Eur Respir J 2006;27:902e7.
4. Agustı´ AGN, Noguera A, Sauleda J, Sala E, Pons J, Busquets X.
Systemic effects of chronic obstructive pulmonary disease. Eur
Respir J 2003;21:347e60.
5. Donaldson GC, Seemungal TA, Patel IS, Bhowmik A,
Wilkinson TM, Hurst JR, et al. Airway and systemic inflamma-
tion and decline in lung function in patients with COPD. Chest
2005;128:1995e2004.
6. Broekhuizen R, Wouters EF, Creutzberg EC, Schols AM. Raised
CRP levels mark metabolic and functional impairment in ad-
vance COPD. Thorax 2006;61:17e22.
7. Sin DD, Lacy P, York E, Man SF. Effects of flucticasone on
systemic markers of inflammation in chronic obstructive pul-
monary disease. Am J Respir Crit Care Med 2004;170:760e5.
8. Fishman D, Faulds G, Jeffery R, Mohamed-Ali V, Yudkin JS,
Humphries S, et al. The effect of novel polymorphisms in the
interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6
levels, and association with systemic onset juvenile arthritis.
J Clin Invest 1998;102:1369e76.
9. Humphries SE, Luong LA, Ogg MS, Hawe E, Miller GJ. The inter-
leukin-6 174G/C promoter polymorphism is associated with
risk of coronary heart disease and systolic blood pressure in
healthy men. Eur Heart J 2001;22:2243e52.
10. Vickers MA, Green FR, Terry C, Mayosi BM, Julier C, Lathrop M,
et al. Genotype at a promoter polymorphism of the interleu-
kin-6 gene is associated with baseline levels of plasma C-
reactive protein. Cardiovasc Res 2002;53:1029e34.
11. Ferrari DL, Ahn-Luong L, Garnero P, Humphries SE,
Greenspan SL. Two promoter polymorphisms regulating inter-
leukin-6 gene expression are associated with circulating levels
of C-reactive protein and markers of bone resorption in post-
menopausal women. J Clin Endocrinol Metab 2003;88:255e9.
12. Seifart C, Dempfle A, Plagens A, Seifart U, Clostermann U,
Mu¨ller B, et al. TNF-a, TNF-b, IL-6, and IL-10 promoter poly-
morphisms in patients with chronic obstructive pulmonary dis-
ease. Tissue Antigens 2005;65:93e100.
13. Broekhuizen R, Grimble RF, Howell WM, Shale DJ,
Creutzberg EC,Wouters EF, et al. Pulmonary cachexia, systemic
inflammatory profile, and the interleukin 1beta 511 single nu-
cleotide polymorphism. Am J Clin Nutr 2005;82:1059e64.
14. Pauwels RA, Buist AS, Ma P, Jenkins CR, Hurd SS. Gold Scientific
Committee. Global strategy for the diagnosis, management
Association of IL-6 gene polymorphisms and COPD 1811and, prevention of chronic obstructive pulmonary disease.
NHLBI/WHO Global Initiative for Chronic Obstructive Lung Dis-
ease (GOLD) workshop summary. Am J Respir Crit Care Med
2001;163:1256e76.
15. Quanjer PH. Standardized lung function testing. Report of the
Working Party for the European Community for Steel and Coal.
Bull Eur Physiopathol Respir 1983;(Suppl. 5):22e7.
16. Pinto-Plata VM, Cote C, Cabral H, Taylor J, Celli BR. The 6-min
walk distance: change over time and value as a predictor of
survival in severe COPD. Eur Respir J 2004;23:28e33.
17. Cabrera de Leo´n A, Gonza´lez DA, Me´ndez LI, Aguirre-Jaime A,
del Cristo Rodrı´guez Pe´rez M, Coello SD, et al. Leptin and alti-
tude in the cardiovascular diseases. Obes Res 2004;12:1492e8.
18. Maca-Meyer N, Villar J, Pe´rez-Me´ndez L, Cabrera de Leo´n A,
Flores C. A tale of aborigines, conquerors and slaves: Alu inser-
tion polymorphism ante peopling of Canary Islands. Ann Hum
Genet 2004;68:600e5.
19. Garcia-Closas M, Lubin JH. Power and sample size calculations
in caseecontrol studies of geneeenvironment interactions:
comments on different approaches. Am J Epidemiol 1999;
149:689e92.
20. Raymond M, Rousset F. GENEPOP (version 1.2): population ge-
netics software for exact tests and ecumenecism. J Hered
1995;86:248e9.
21. Barret JC, Fry B, Maller J, Daly MJ. Haploview: analysis and vi-
sualization of LD and haplotype maps. Bioinformatics 2005;21:
263e5.
22. Stephens M, Donnelly P. A comparison of Bayesian methods for
haplotype reconstruction. Am J Hum Genet 2003;73:1162e9.
23. Nyholt DR. A simple correction for multiple testing for SNPs in
linkage disequilibrium with each other. Am J Hum Genet 2004;
74:765e9.
24. Bennermo M, Held C, Green F, Strandberg LE, Ericsson CG,
Hansson LO, et al. Prognostic value plasma interleukin-6 con-
centrations and the 174G> C and 572G> C promoterpolymorphisms of the interleukin-6 gene in patients with acute
myocardial infarction treated with thrombolysis. Atherosclero-
sis 2004;174:157e63.
25. Brull DJ, Montgomery HE, Sanders J, Dhamrait S, Luong L,
Rumley A, et al. Interleukin-6 gene 174G> C and
572G> C promoter polymorphisms are strong predictors of
plasma inteleukin-6 levels after coronary artery bypass sur-
gery. Arterioscler Thromb Vasc Biol 2001;21:1458e63.
26. Shin KK, Jang Y, Koh SJ, Kim OY, Choi D, Shin DJ, et al. Influ-
ence of the IL-6 572C>G polymorphism on inflammatory
markers according to cigarette smoking in Korean healthy
men. Cytokine 2007;39:116e22.
27. Terry CF, Louckaci V, Green FR. Cooperative influence of ge-
netic polymorphism on interleukin 6 transcriptional regulation.
J Biol Chem 2000;275:18138e44.
28. Mu¨ller-Steinhardt M, Frickle L, Mu¨ller B, Ebel B, Kirchner H,
Ha¨rtel C. Cooperative influence of the interleukin-6 promoter
polymorphisms 597, 572 and 174 on long term kidney allo-
graft survival. Am J Transplant 2004;4:402e6.
29. Snider GL. Understanding inflammation in chronic obstructive
pulmonary disease: the process begins. Am J Respir Crit Care
Med 2003;167:1045e6.
30. van Helvoort HA, Heijdra YF, Heunks LM, Meijer PL,
Ruitenbeek W, Thijs HM, et al. Supplemental oxygen prevents
exerciseeinduced oxidative stress in muscle-wasted patients
with chronic obstructive pulmonary disease. Am J Respir Crit
Care Med 2006;173:1122e9.
31. Joppa P, Petrasova D, Stancak B, Tkacova R. Systemic inflam-
mation in patients with COPD and pulmonary hypertension.
Chest 2006;130:326e33.
32. Yokoe T, Minoguchi K, Matsuo H, Oda N, Minoguchi H,
Yoshino G, et al. Elevated levels of C-reactive protein and in-
terleukin-6 in patients with obstructive sleep apnea syndrome
are decreased by nasal continuous positive airway pressure.
Circulation 2003;107:1129e34.
